Thanks for the reminder gbr and there may be a few resurrected work plans among those divested brands - I remember previously discussing Max Factor, CoverGirl, Dolce & **bana, Wella, Clairol, Nice & Easy, Natural Instincts & Sassoon; but let's face it - even if they were previously a 'work plan' and are in the process of being resurrected...they will take their sweet time; no doubt imo. Your post has put me in a nostalgic mood, which made me dig out the Term Sheet for COTY and their Philosophy brand from three years ago. I really do wonder exactly what is transpiring behind the curtain here...if anything:
And then I came across this post from captainblood (the nicer one) with 91 TU after the 2015 AGM; where there also appears to be either no progress, on the back-burner, not going ahead. BodyGuard seems to offer the only promise atm out of everything mentioned in captainblood's post. Knowledge is definately power when it comes to keeping an eye on your investments:
'Just some quick notes while I am in the airport
Wave 2 are in the process of discussing launch
Companies mentioned I hadn't heard before, l'oreal ( jeff will be in Paris in the next 2 weeks), Johnson and Johnson and brooks footwear concerning bodyguard
Bodyguard is a double blind test and they won't have results until mid January, but have p&g with first look, rb -neurogen 2nd and then GSk voltaren 3rd lining up to see them Royalties with both p&g and coty are on final sale price. Eg eye cream $100 + $2 wand they sell for $149. We get our cut of the 149. With the initial eye wand launch we gave p&g some concessions, so that would be why the figures are small so far.plus we get our cut after the sale so revenue takes time to filter thru
Also mentioned Gillette with shaving
That's my flight being called I will add more after I decipher my scribbles.' https://hotcopper.com.au/threads/an...2643786/page-71?post_id=16444218#.We_gOFuCze5
We now know from the recent Investor Conference call that Gillette is on the back-burner, royalties are on wholesale, Reckitt Benckiser - Nurofen have walked away from Advanced Packaging with no explanation and there is still a deathly silence on GSK Voltaren, Johnson & Johnson and L'Oreal. Does this silence mean that we will get an update from the OBJ BoD in a couple of years time advising that these companies have also not proceeded, been delayed or are now on the back-burner? Your guess is as good as mine.
On a more up-beat note, the Quarterly should be out in less than 5 working days.
OBJ Price at posting:
3.3¢ Sentiment: Buy Disclosure: Held
(20min delay)